238 related articles for article (PubMed ID: 21705685)
1. Hyperoxia therapy of pre-proliferative ischemic retinopathy in a mouse model.
Zhang W; Yokota H; Xu Z; Narayanan SP; Yancey L; Yoshida A; Marcus DM; Caldwell RW; Caldwell RB; Brooks SE
Invest Ophthalmol Vis Sci; 2011 Aug; 52(9):6384-95. PubMed ID: 21705685
[TBL] [Abstract][Full Text] [Related]
2. TMP prevents retinal neovascularization and imparts neuroprotection in an oxygen-induced retinopathy model.
Liang X; Zhou H; Ding Y; Li J; Yang C; Luo Y; Li S; Sun G; Liao X; Min W
Invest Ophthalmol Vis Sci; 2012 Apr; 53(4):2157-69. PubMed ID: 22410554
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic interference with EphrinB2 signalling inhibits oxygen-induced angioproliferative retinopathy.
Ehlken C; Martin G; Lange C; Gogaki EG; Fiedler U; Schaffner F; Hansen LL; Augustin HG; Agostini HT
Acta Ophthalmol; 2011 Feb; 89(1):82-90. PubMed ID: 19764912
[TBL] [Abstract][Full Text] [Related]
4. Effects of sustained hyperoxia on revascularization in experimental retinopathy of prematurity.
Gu X; Samuel S; El-Shabrawey M; Caldwell RB; Bartoli M; Marcus DM; Brooks SE
Invest Ophthalmol Vis Sci; 2002 Feb; 43(2):496-502. PubMed ID: 11818396
[TBL] [Abstract][Full Text] [Related]
5. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade.
Ristori C; Filippi L; Dal Monte M; Martini D; Cammalleri M; Fortunato P; la Marca G; Fiorini P; Bagnoli P
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):155-70. PubMed ID: 20739470
[TBL] [Abstract][Full Text] [Related]
6. Association of retinal vascular endothelial growth factor with avascular retina in a rat model of retinopathy of prematurity.
Budd SJ; Thompson H; Hartnett ME
Arch Ophthalmol; 2010 Aug; 128(8):1014-21. PubMed ID: 20697002
[TBL] [Abstract][Full Text] [Related]
7. Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF/VEGFR2 pathway.
Liu H; Zhang W; Xu Z; Caldwell RW; Caldwell RB; Brooks SE
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):918-31. PubMed ID: 23307955
[TBL] [Abstract][Full Text] [Related]
8. Soluble forms of EphrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy.
Zamora DO; Davies MH; Planck SR; Rosenbaum JT; Powers MR
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2175-82. PubMed ID: 15914639
[TBL] [Abstract][Full Text] [Related]
9. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity.
Pierce EA; Foley ED; Smith LE
Arch Ophthalmol; 1996 Oct; 114(10):1219-28. PubMed ID: 8859081
[TBL] [Abstract][Full Text] [Related]
10. Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy.
McLeod DS; Taomoto M; Cao J; Zhu Z; Witte L; Lutty GA
Invest Ophthalmol Vis Sci; 2002 Feb; 43(2):474-82. PubMed ID: 11818393
[TBL] [Abstract][Full Text] [Related]
11. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy.
Chen J; Connor KM; Aderman CM; Willett KL; Aspegren OP; Smith LE
Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1329-35. PubMed ID: 18952918
[TBL] [Abstract][Full Text] [Related]
12. Cysteine-rich 61, a member of the CCN family, as a factor involved in the pathogenesis of proliferative diabetic retinopathy.
You JJ; Yang CH; Chen MS; Yang CM
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3447-55. PubMed ID: 19264885
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal Delivery of VEGF-A
Mezu-Ndubuisi OJ; Wang Y; Schoephoerster J; Falero-Perez J; Zaitoun IS; Sheibani N; Gong S
Curr Eye Res; 2019 Mar; 44(3):275-286. PubMed ID: 30383455
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of VEGF by retinoic acid during hyperoxia prevents retinal neovascularization and retinopathy.
Wang L; Shi P; Xu Z; Li J; Xie Y; Mitton K; Drenser K; Yan Q
Invest Ophthalmol Vis Sci; 2014 May; 55(7):4276-87. PubMed ID: 24867581
[TBL] [Abstract][Full Text] [Related]
15. Reduced retinal neovascularization, vascular permeability, and apoptosis in ischemic retinopathy in the absence of prolyl hydroxylase-1 due to the prevention of hyperoxia-induced vascular obliteration.
Huang H; Van de Veire S; Dalal M; Parlier R; Semba RD; Carmeliet P; Vinores SA
Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7565-73. PubMed ID: 21873682
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic effect of betaine on pathologic retinal neovascularization via suppression of reactive oxygen species mediated vascular endothelial growth factor signaling.
Park SW; Jun HO; Kwon E; Yun JW; Kim JH; Park YJ; Kang BC; Kim JH
Vascul Pharmacol; 2017 Mar; 90():19-26. PubMed ID: 27473515
[TBL] [Abstract][Full Text] [Related]
17. T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification.
Banin E; Dorrell MI; Aguilar E; Ritter MR; Aderman CM; Smith AC; Friedlander J; Friedlander M
Invest Ophthalmol Vis Sci; 2006 May; 47(5):2125-34. PubMed ID: 16639024
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor-B and retinal vascular development in the mouse.
Reichelt M; Shi S; Hayes M; Kay G; Batch J; Gole GA; Browning J
Clin Exp Ophthalmol; 2003 Feb; 31(1):61-5. PubMed ID: 12580897
[TBL] [Abstract][Full Text] [Related]
19. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity.
Stone J; Chan-Ling T; Pe'er J; Itin A; Gnessin H; Keshet E
Invest Ophthalmol Vis Sci; 1996 Feb; 37(2):290-9. PubMed ID: 8603833
[TBL] [Abstract][Full Text] [Related]
20. Role of nonproteolytically activated prorenin in pathologic, but not physiologic, retinal neovascularization.
Satofuka S; Ichihara A; Nagai N; Koto T; Shinoda H; Noda K; Ozawa Y; Inoue M; Tsubota K; Itoh H; Oike Y; Ishida S
Invest Ophthalmol Vis Sci; 2007 Jan; 48(1):422-9. PubMed ID: 17197563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
